Cytokine Profile of Conjunctivitis, Performed Through Tears Analysis Among Patients Treated With Dupilumab
NCT ID: NCT04066998
Last Updated: 2019-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
15 participants
INTERVENTIONAL
2019-12-31
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
NCT04296864
Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months
NCT02057822
Tofacitinib for Inflammatory Eye Disease
NCT03580343
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
NCT00349466
Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia
NCT00383396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Conjunctivitis
Patients treated with Dupilumab with conjunctivitis
Tears sampling
Tears sampling
Lashes sampling
Lashes sampling
No conjunctivitis
Patients treated with Dupilumab and showing no signs of ocular involvement
Tears sampling
Tears sampling
Lashes sampling
Lashes sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tears sampling
Tears sampling
Lashes sampling
Lashes sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treated with Dupilumab
* with or without conjunctivitis
* postmenopausal women (since minimum 24 months), surgically sterilized women or women on contraception
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille FEBVAY, MD
Role: PRINCIPAL_INVESTIGATOR
CHU de Besançon
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P/2019/424
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.